[1]
A. Ciapponi, “Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis”, Rev Peru Med Exp Salud Publica, vol. 41, no. 1, pp. 7–18, Mar. 2024, doi: 10.17843/rpmesp.2024.411.13351.